The Swiss pharmaceutical company learned that some of its employees had manipulated data in the Zolgensma application in March, but instead of telling the Food and Drug Administration immediately, Novartis conducted its own investigation and submitted the results to the FDA in late June, about one month after Zolgensma was approved by the FDA.
In a letter to Novartis CEO Vas Narasiman, Mr. Grassley asked the company to provide all records about the issue, including results of its internal inquiry and the number of employees terminated as a result of the error.
Mr. Narasiman was given a deadline of Aug. 23 to respond to the letter.
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.